E2 ModerateModerate confidencePEM not requiredCross-SectionalPeer-reviewedMachine draft
Peripheral Levels of Selected Biomarkers in Patients with Post-Sarcoidosis Chronic Fatigue Syndrome.
Małujło-Balcerska, Elżbieta, Bączek, Karol, Górski, Witold et al. · Journal of inflammation research · 2025 · DOI
Quick Summary
This study looked at 71 people with sarcoidosis (a disease that causes inflammation) to understand why some feel extremely tired even after their disease improves. Researchers measured inflammation markers in the blood and found that people with lingering fatigue had higher levels of a protein called IL-6 compared to those without fatigue. The findings suggest that low-grade inflammation may be keeping people fatigued even when their disease appears to be under control.
Why It Matters
This study identifies IL-6-mediated inflammation as a potential mechanism underlying persistent fatigue even during disease remission, paralleling hypotheses in ME/CFS and Long COVID pathogenesis. The findings suggest IL-6 as a tractable biomarker and therapeutic target for post-inflammatory fatigue syndromes, informing future intervention development for ME/CFS patients.
Observed Findings
- Fatigued patients in remission (RS/CFS) and those with active disease showed significantly higher hsCRP and IL-6 levels compared to non-fatigued remission patients (p<0.05).
- IL-6 demonstrated moderate positive correlation with both fatigue severity (r=0.33) and depressive symptoms (r=0.33).
- No significant differences were detected in TNF-α or oxidative stress markers (total antioxidant status, 8-isoprostanes) between fatigue groups.
- Pulmonary function was slightly reduced in fatigued patients and weakly correlated with mental fatigue (r=-0.26).
- Fatigue and depressive symptom scores were significantly elevated in RS/CFS and A/S groups versus R/S (p<0.05).
Inferred Conclusions
- Low-grade systemic inflammation, particularly elevated hsCRP and IL-6, is associated with fatigue and depressive symptoms during sarcoidosis remission.
- IL-6 may represent a potential biomarker for detecting and monitoring fatigue in sarcoidosis patients.
- Persistent low-grade inflammation rather than active granulomatous disease may drive post-inflammatory fatigue syndromes.
- Integrated investigation of inflammatory, oxidative, metabolic, and neuroendocrine pathways is needed to fully understand fatigue pathogenesis and guide therapeutic development.
Remaining Questions
What This Study Does Not Prove
This study does not prove that IL-6 causes fatigue—only that they are associated in sarcoidosis remission. Cross-sectional design prevents determination of temporal relationships or causality. Findings are specific to post-sarcoidosis fatigue and may not directly apply to ME/CFS or other fatigue etiologies without further validation.
Tags
Symptom:Cognitive DysfunctionPainFatigue
Biomarker:CytokinesBlood Biomarker
Method Flag:PEM Not DefinedWeak Case DefinitionSmall SampleMixed Cohort
Metadata
- DOI
- 10.2147/JIR.S549445
- PMID
- 41357843
- Review status
- Machine draft
- Evidence level
- Single-study or moderate support from human research
- Last updated
- 8 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →